Corporate Information

555 California Street
Suite 365
San Francisco, CA 94104

Phone: 415-568-2245
Fax: 415-568-2104

www.medgenics.com 

 

Recent News Releases

Friday, May 18, 2012
Friday, May 18, 2012
[Business Wire] - Medgenics, Inc. , the developer of the novel Biopump™ technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Andrew L.
Thursday, May 17, 2012

Follow Me

Medgenics Inc.

Corporate Snapshot

Medgenics Inc. ("Medgenics" or "the Company") is a clinical-stage biopharmaceutical company developing a platform technology to provide sustained-action protein therapy for chronic diseases, initially anemia and hepatitis C. As an alternative to today's protein therapy, which involves frequent bolus injections of proteins, Medgenics is developing a biological pump, called the Biopump, made using a patient's own skin. Directly addressing a protein therapeutic market forecast to be $87 billion by 2010, the Biopump works inside the body to produce and deliver active protein steadily for a sustained duration to treat a targeted indication. The platform employs a sliver of dermal tissue, which is harvested from under the patient's skin and engineered to manufacture and distribute the required therapeutic protein using well-established protein production methods. The tissue is processed ex vivo using a viral vector having non-immunogenic properties, which carries the appropriate gene into the nuclei of the tissue's cells and causes them to produce the selected protein, converting the dermal tissue into a sustained-action Biopump. In 10 to 14 days after the harvest, the Biopump is reinserted into the patient in order to supply the active protein to the patient for several months. A protein production plant in the patient, the Biopump is intended to replace the need for frequent, costly, and painful injections and avoid their side effects. The Company is currently developing its first two products based on its sustained-action Biopump technology: (1) EPODURE producing EPO to treat anemia; and (2) INFRADURE producing interferon-alpha (IFN-a) to treat hepatitis C. The Biopump platform is also intended to produce other proteins to treat conditions such as multiple sclerosis, hemophilia, pediatric growth deficiencies, and diabetes, among others. Medgenics trades on the London Stock Exchange's (LSE) Alternative Investment Market (AIM).

* The Corporate Snapshot was last updated on September 8, 2009.

Latest Research

Quarterly
Update

2009-09-08

Click to View

 

Quarterly
Update

2009-02-27

Click to View

 

Executive
Informational
Overview

2006-10-16

Click to View

 

Stock Information (MDGN-AMEX)